Impact and Barriers of the Health Insurance Review on Splitting Extended-Release Formulation Drugs

서방형제제 분할처방에 대한 건강보험심사제도의 효과와 장애요인

  • Jang, Hye-Min (Graduate School of Clinical Pharmacy, Sookmyung Women's University) ;
  • Lee, Eui-Kyung (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
  • 장혜민 (숙명여자대학교 임상약학대학원) ;
  • 이의경 (숙명여자대학교 임상약학대학원)
  • Received : 2011.09.06
  • Accepted : 2011.11.22
  • Published : 2011.12.31

Abstract

Health insurance review & Assessment service (HIRA) has enforced cutting the drug costs when physicians prescribe split extended release drugs, starting from December, 2010. The objective of this study is to analyze extended release and enteric coated drugs on pharmaceutical reimbursement list in Korea, and to investigate the impact and barriers of the health insurance review on splitting extended-release formulation drugs. By using the ingredient code, extended release and enteric coated formulations make up 7.8% of all drugs in April, 2011. The most frequently used drugs are agent affecting circulatory and digestive system. From the extended release and enteric coated formulations (n=112), 34.8% (n=39) were not available in other dosage forms. According to questionnaire survey for 169 pharmacists (response rate: 73.8%), the rate of splitting and crushing of extended release and enteric coated drugs decreased. When pharmacists correct physician's prescription errors, the biggest problem was lack of other dosage forms. So it is necessary to develop variety of other dosage forms, and computerized checking system for splitting extended-release drugs. It is also important to inform physicians and patients in regard to the problems of split prescription of extended release and enteric coated drugs.

Keywords